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Bowel Perfusion Measured with Dynamic Contrast-enhanced
Ultrasound Predicts Treatment Outcome in Patients with
Crohn’s Disease
Fredrik Saevik,*,† Kim Nylund, MD, PhD,*,† Trygve Hausken, MD, PhD,*,† Svein Ødegaard, MD, PhD,*,†
and Odd H. Gilja, MD, PhD*,†
Background: To improve management of patients with Crohn’s disease (CD), objective measurements of the degree of local inﬂammation in the
gastrointestinal wall are needed. Increased microvessel density and perfusion are typical features of acute inﬂammation and can be estimated with
contrast-enhanced ultrasound (CEUS). The aim of the study was to investigate whether CEUS can provide prognostic information about patients treated
medically for an acute exacerbation of CD.
Methods: Fourteen patients with CD who received medical treatment for acute exacerbation with systemic steroids or tumor necrosis factor–a inhibitors
were prospectively recruited. The patients were examined with clinical scoring, blood tests, and CEUS at time 0, 1, 3, and 12 months after initiation of the
treatment. Outcome was treatment efﬁcacy or treatment failure deﬁned as change in medical treatment after 1 month or later. The perfusion analysis was
performed with a commercially available software program that analyzes the contrast intensity in a selected area, ﬁts the data to a standardized time-
intensity curve, and derives several relative perfusion parameters.
Results: Six of the 14 patients had treatment failure during the study period. There was a signiﬁcant difference between the groups for peak contrast
enhancement (P ¼ 0.013), rate of wash-in (P ¼ 0.020) and wash-out (P ¼ 0.008), and the area under the time-intensity curve in the wash-in phase
(0.013) at the examination 1 month after the start of treatment.
Conclusions: Perfusion analysis of the intestinal wall with CEUS 1 month after starting treatment in patients with CD can provide prognostic
information regarding treatment efﬁcacy.
(Inﬂamm Bowel Dis 2014;20:2029–2037)
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C ommonly, acute exacerbation of Crohn’s disease (CD) is trea-ted with systemic steroids or tumor necrosis factor–a (TNF-a)
inhibitors.1 Currently, there are no optimal methods for assessing
the efﬁcacy of a treatment regime. In daily clinical practice, gastro-
intestinal (GI) endoscopy is normally used to evaluate disease
activity in the GI-tract, but most of the small bowel, subepithelial
structures, or extraintestinal complications cannot be visualized with
this technique. There are also other limitations with endoscopy, such
as risk of perforation, difﬁculties to pass stenosis, and patient dis-
comfort. Therefore, cross-sectional imaging modalities such as com-
puted tomography, ultrasonography (US), and magnetic resonance
imaging (MRI) have become increasingly important.2 Ultrasonog-
raphy seems to perform equally well as both computed tomography
and MRI, e.g., in detection of disease and complications as well as
in mapping extent and disease activity.3,4 Ultrasonography is more
operator- and patient-friendly than other imaging methods because
new machines are small, portable, relatively inexpensive, and non-
invasive and is thus suitable for bed-side examination.5 Conse-
quently, it is a modality well suited for the repeated examinations
needed when evaluating treatment effect.
Contrast-enhanced ultrasound (CEUS) can be used for
estimation of bowel wall perfusion.6–8 This is important because
neovascularization in the GI wall is a histological ﬁnding in active
CD related to the degree of inﬂammation. Also, the autoregulation
of the blood supply in the bowel wall is dysfunctional in these
patients.9–11
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There seems to be a correlation between the enhancement
from the ultrasound contrast agent, microvessel density,12 and the
histological degree of inﬂammation.13 Several authors have also
shown that there is a relationship between contrast enhancement
and disease activity in CD both for CEUS and MRI.4,14–16 Ana-
lyzing the degree of enhancement from ultrasound contrast
agents, however, require strict standardization and is thus imprac-
tical in daily clinical work. Dynamic contrast-enhanced ultra-
sound (DCE-US) or analysis of the time evolvement of contrast
enhancement may be more robust because it is more closely
related to the perfusion parameters. Although several studies show
that relative perfusion parameters derived from DCE-US are
related to disease activity and can separate inﬂammation and
ﬁbrosis,7,17–20 few studies have implemented this method in lon-
gitudinal studies of treatment outcome.
Already in 2002 using the ultrasound contrast agent Levovist,
Di Sabatino et al21 found that in a subset of patients with quiescent
disease and contrast enhancement, the disease relapsed after 6 months.
Recently 2 prospective longitudinal studies were published using
endoscopy as reference standard. Moreno et al22 examined patients
before treatment and after 1 year with CEUS and found that bowel
wall thickness predicted endoscopic remission better than contrast
enhancement. Ordas et al23 examined patients before treatment and
after 3 months using an MRI score including contrast enhancement
and found a good correlation with endoscopy and an accuracy of 83%
for predicting mucosal healing. These studies focus on contrast
enhancement not perfusion, but in a recent study by Quaia et al,24
they found a difference in relative perfusion 3 months after initiation
of treatment between treatment responders and nonresponders. This
was a cross-sectional study, however, not including data from the start
of the treatment or data on bowel wall thickness, which previously has
been shown to be related to treatment outcome.25,26
The aim of this pilot study was to evaluate whether perfusion
parameters derived from DCE-US of affected bowel with commer-
cially available software can be used for monitoring disease activity in
patients with CD. As a secondary aim, we wanted to examine when
the most appropriate time to perform the follow-up examination was.
MATERIALS AND METHODS
The study was a prospective pilot study with 12-month
follow-up performed in a single center.
Patients
Twenty patients with acute exacerbation of CD, scheduled
for treatment with systemic steroids, adalimumab, or inﬂiximab
were prospectively recruited from the outpatient clinic or the
bedward at the Section of Gastroenterology at Haukeland
University Hospital. Inclusion criteria were acute exacerbation
FIGURE 1. Different quantitative perfusion parameters derived from Vuebox. The parameters with their abbreviations are enlisted in the left panel,
whereas the ﬁgure in the right panel shows how they are derived from the time-intensity curve (the ﬁgure is based on a corresponding ﬁgure in
the Vuebox instruction manual).
TABLE 1. Different Quantitative Perfusion Parameters
with Corresponding Deﬁnitions, Derived from the
Modeled Time-intensity Curve (TIC) in Vuebox
Parameter Abbreviation Deﬁnition
Peak enhancement PE Indicates the maximum intensity of
the TIC
Wash-in area under
the curve
WiAUC Area under the TIC from time of
arrival to the PE
Rise time RT Time from arrival of contrast to PE
Mean transit time MTT Average time for the blood to pass
through the region of interest
Wash-in rate WiR The maximum slope of the TIC
represented as a tangent at the
ascending part of the curve
Wash-out area
under the curve
WoAUC The area under the TIC from the PE
to the end of the curve
Wash-in/wash-out
area under the
curve
WiWoAUC The total area under the TIC
Fall time FT Time from PE to a point at the x-axis
where the minimum slope tangent
crosses
Wash-out rate WoR The minimum slope of the curve.
Represented as a tangent at the
descending part of the curve
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of CD with Crohn’s disease activity index (CDAI) .150 requir-
ing medical treatment with either systemic steroids or anti-TNF’s,
such as inﬂiximab or adalimumab. Exclusion criteria were normal
transabdominal ultrasound, abscess, perforation, or stenosis
requiring surgery during the ﬁrst month of follow-up, pregnancy,
age ,18 years, acute coronary or pulmonary failure, or allergy
against the medical treatment or the ultrasound contrast agent. The
patients were recruited from 2009 to 2012. The study was obser-
vational and decision-to-treat or change treatment was made by
a physician without knowledge of the CEUS ﬁndings. Each
patient underwent clinical scoring as well as blood and stool
sampling at the start of the study and 1, 3, and 12 months into
the follow-up period. Ileocolonoscopy was performed before
study start to conﬁrm disease status.
Clinical and Biochemical Tests
Patient history, demographic data, and current treatment
regime were collected through patient interviews and/or access to
medical records. Each patient was scored according to the Montreal
classiﬁcation.27 CDAI was registered before the ultrasound exam-
ination. Blood and stool samples were collected within 1 week after
the ultrasound examination. Hemoglobin (g/dL), leukocyte count
(109/L), platelet count (109/L), C-reactive protein (mg/L), and
Albumin (mg/L) were measured in the blood, whereas the stool
was analyzed for calprotectin (mg/mg).
FIGURE 2. CEUS of the intestine in a patient with CD. A, the ultrasound image is presented as B-mode to the left and in a contrast mode to the right.
B, Enhancement with Sonovue linearized to arbitrary units together with the modeled time-intensity curve. C, Ultrasound-image with B-mode to the
left and a parametric color map covering the contrast image to the right. D, Table displays the quantitative data obtained from the analysis.
TABLE 2. Montreal Classiﬁcation, Gender, and
Outcome for Each Patient with CD Examined in the
Study
Patient Gender
Montreal Classiﬁcation Effective
TreatmentAge Location Behavior
1 Female A2 L2 B1 No
2 Male A2 L1 B2 Yes
3 Female A2 L3 B1 Yes
4 Male A2 L3 B1p No
5 Male A2 L3 B1 Yes
6 Male A3 L1 B3 No
7 Female A3 L2 B1 Yes
8 Male A2 L2 B1 Yes
9 Male A3 L2 B1 Yes
10 Male A2 L3 B1 No
11 Female A2 L2 B2 No
12 Female A3 L2 B1 Yes
13 Male A2 L1 B2 No
14 Male A2 L3 B1 Yes
Age of diagnosis: A1 ,16 years; A2 ¼ between 17 and 40 years; A3 .40 years; Location:
L1 ¼ ileal; L2 ¼ colonic; L3 ¼ ilecocolonic; L4 ¼ isolated upper disease; Behavior: B1 ¼
nonstricturing, nonpenetrating; B2 ¼ stricturing; B3 ¼ penetrating; p ¼ perianal disease.
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Ultrasound Examination
Ultrasound was performed with a Logiq E9 ultrasound
scanner (GE Healthcare, Milwaukee, WI), using a convex probe
(C1-5, 1–6 MHz) for abdominal overview, a linear probe (ML6-
15, 9–15 MHz) for detailed examination of the intestinal wall and
a linear transducer (9L, 5.5–9 MHz) for the CEUS examination.
All segments of the small and large bowel were examined. A
small and large bowel wall thickness .2 mm was considered
pathological if the bowel lumen diameter was .0.5 cm and
.3 mm if the lumen diameter was ,0.5 cm or collapsed. The
length of the affected bowel wall, the bowel wall thickness, and
the thickness of the individual ultrasound layers were measured
as previously described.28,29 The ultrasound layers correspond
closely to the mucosa, submucosa, and proper muscle of the
GI wall.30 The thickest wall section was chosen for further
examination.
DCE-US was performed using Sonovue (Bracco, Milan,
Italy) and the contrast mode on the ultrasound scanner. In
contrast mode, we used the general setting with color map 2.0,
dynamic range 60, MI between 0.09 and 0.12, gain adjusted to
reduce background tissue signal, and focus just behind the
affected bowel wall. Two contrast injections were performed.
First, the right iliac artery was examined and acted as a reference.
The ultrasound probe was positioned over the right iliac
artery so that it could be seen at approximately the same depth
as the affected bowel and then 0.4 mL of Sonovue was injected
over 2 seconds followed by a ﬂush of 10 mL of saline over
4 seconds. For the second injection, 4.4 mL of Sonovue and
10 mL of saline with the same time intervals was given with the
imaging plane in the longitudinal direction of the affected
anterior bowel wall. This was done 5 to 10 minutes after the
ﬁrst bolus when no contrast signal could be seen in the affected
bowel wall. A 60-second cine loop was recorded and exported as
Digital Imaging and Communications in Medicine (DICOM) for
further analysis.
Quantitative CEUS Analysis
The analysis of the DICOM contrast recordings was
performed with dedicated, commercially available software
for perfusion analysis (Vuebox; Bracco Suisse SA, Geneva,
Switzerland). Vuebox is a quantiﬁcation software, which eval-
uates the CEUS data, based on signal intensity changes over
time.8 The software converts the exported DICOM video data to
linear intensity units using conversion algorithms speciﬁc for each
TABLE 3. Therapy, Clinical, and Sonographic Features for Each Patient with CD at Each Time Point in the Study
Patient
Therapy CDAI
Bowel Wall
Thickness, mm
Length of
Affection, cm
Affected Bowel SegmentsExamination Time, mo
0 1 3 12 0 1 3 12 0 1 3 12 0 1 3 12 0 1 3 12
1 S S S IFX 246 266 67 38 2.4 2.8 7.4 2.0 19.5 15.3 42.9 0 TI, AC,
DC, SC
AC, TC,
DC, SC
AC, TC,
DC, SC
2 S S ADA ADA 235 235 47 26 6.8 6.8 7.6 5.2 9.9 9.9 10.8 9.3 TI TI TI TI
3 ADA ADA ADA ADA 237 57 42 66 5.0 1.1 3.0 1.6 15.8 17.6 31.7 0 AC, TC AC, T C AC, TC,
DC, RE
4 S S IFX 236 135 94 89 2.9 3.3 3.5 1.8 5.2 4.0 10.4 0 TC, RE TC TC, SC
5 S S 396 151 126 175 2.6 3.2 4.6 6.5 11.2 5.1 7.0 10 TI, DC TI TI TI
6 IFX IFX IFX IFX 245 67 196 NA 6.7 7.2 8.0 NA 13.8 15.7 11.4 NA TI TI TI
7 S S S 174 133 180 180 4.1 4.4 2.4 1.9 10.3 21.3 15.9 0 DC, SC, RE DC, SC,
RE
DC, SC
8 S S 462 148 76 12 3.7 4.6 1.8 1.2 23.5 12.6 4.7 0 AC, TC, DC TC, AC AC
9 S S 374 71 0 30 6.3 0.8 4.5 1.4 32.0 5.4 16.9 0 AC, TC, DC,
SC, RE
DC AC, TC
10 S S ADA 247 241 235 13 4.9 8.1 4.6 2.0 26.7 27.3 17.8 3.0 TI, AC, TC,
DC, SC
TI, AC, SC TI, AC, SC AC
11 S, ADA S, ADA ADA IFX 288 223 217 143 4.7 5.6 3.9 5.0 23.6 17.3 12.6 38.7 TC, DC, SC SC AC, SC AC, SC,
RE
12 S, IFX IFX IFX IFX 406 134 36 36 3.4 4.6 4.0 1.0 23.0 17.0 15.7 0 AC, TC, DC AC, TC AC, TC,
SC
13 S S S ADA 160 0 6.0 30 6.0 5.3 6.8 7.1 12.4 17.3 11.2 12.6 TI TI TI TI
14 S, ADA S, ADA ADA ADA 400 95 81 21 4.3 2.7 1.6 2.4 13.1 13.6 6.6 7.3 AC, TI AC, TI TI TI
For patients that changed drug regime the new therapy is shown in bold. 0 ¼ Before treatment start; 1 ¼ 1 month after treatment; 3 ¼ 3 months after treatment; 12 ¼ 12 months after
treatment; S, systemic steroids; Adalimumab, ADA; Inﬂiximab, IFX; NA, not available; I, ileum; TI, terminal ileum; AC, ascending colon; TC, transverse colon; DC, descending colon;
SC, sigmoid colon; RE, rectum.
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probe, color map, and dynamic range.31 The reconstructed echo-
power data are directly proportional to the concentration of the
microbubbles within the dose range used,32 and as a function of
time, these time-intensity signals are ﬁtted to a standardized curve,
from which several parameters can be derived (Fig. 1). Vuebox
provides parameters related to signal amplitude, time, and a com-
bination of amplitude and time (Table 1) by using wash-in/wash-
out kinetics. Because of a proportional relationship between the
perfusion parameters derived from Vuebox and regional blood
ﬂow, quantitative measurements are possible. The parameters
are expressed in arbitrary units, providing perfusion parameters
relative to the actual perfusion.8 Thus, the clinician is only able to
assess whether an area of interest is hyper-, hypo-, or isoperfused
in relation to the surrounding tissue. By normalizing the affected
area to an internal reference such as the right iliac artery, perfu-
sion parameters from different examinations can be compared.
The workﬂow in the software consists of uploading the
DICOM ﬁle, choosing the relevant probe calibration, deleting off
plane frames, and choosing an area of interest that is automatically
motion corrected. Then the examiner draws a region of interest
and marks the time of contrast arrival before the software analyses
the time-intensity data (Fig. 2).8 The resulting amplitude-related
parameters from the examined bowel wall were exported in an
excel sheet and normalized by dividing the perfusion parameters
expressed in arbitrary units with the corresponding parameters
from the right iliac artery. The time-related parameters are inde-
pendent of contrast concentration making normalization
unnecessary.
Outcomes
The endpoints were clinical remission or treatment failure
during the follow-up period. Clinical remission was deﬁned as
CDAI ,150 after 12 months of treatment start. Treatment failure
was deﬁned as a change in the drug regime .1 month after
treatment start from systemic steroids to anti-TNF or from one
anti-TNF to another during the follow-up period. Effective treat-
ment was deﬁned as continued use of same anti-TNF or discon-
tinuation of systemic steroids during the study period. If a patient
had to change treatment due to drug’s side effects, this was not
considered a treatment failure. Treatment change was done by
a clinician unaware of the perfusion measurements.
Statistics
The data were analyzed using descriptive statistics and
presented with median, minimum, and maximum values. Further
comparison of continuous data between the groups was performed
using the Student’s t test or the Mann–Whitney U test. The level
of signiﬁcance was P , 0.05. The data analysis was performed
using IBM SPSS Statistics software (version 20 for Windows;
IBM Inc., Armonk, NY).
Ethical Considerations
The study was approved by the Regional Ethical Commit-
tee for Medical and Health Research in Western Norway (REK).
Each patient signed informed consent before participating in the
study.
RESULTS
During the study period, 2 patients withdrew from the
study, 1 was lost to follow-up, 1 was diagnosed with bowel
perforation within 1 month after inclusion, 1 required acute
surgery due to bowel obstruction during the ﬁrst month, and in 1
case, the contrast data were incomplete and could not be analyzed.
The remaining 14 patients were 5 women and 9 men with
a median age of 33 years (range, 20–50 yr). The Montreal clas-
siﬁcation for each patient is shown in Table 2. At 12 months, 11
patients were in clinical remission, 2 had still active disease and 1
had surgical resection of the affected area. The treatment failed in
6 of 14 patients during the study period. Because 11 of 14 patients
were in remission at the end of the study, a statistical comparison
was not done between the groups. In Table 3, an overview of the
therapy, clinical, and sonographic features for each patient at each
time point in the study is shown.
There were no signiﬁcant differences between the effective
treatment group and treatment failure group, in the demograph-
ical, biochemical, and clinical data for any of the time points
during the study. In Table 4, these data are shown for the exam-
ination done at the start of the study. Also, there were no signif-
icant differences for the ultrasound measurements of the bowel
wall thickness and the length of the affected bowel. However,
there were signiﬁcant differences in the bowel wall layers. The
TABLE 4. Demographical, Biochemical, and Clinical
Data of Patients with CD Measured at the Initiation of
the Treatment
Biochemical or Clinical Marker
Effective Treatment Treatment Failure
Median (Range) Median (Range)
Age, yr 43 (20–49) 32 (22–50)
Years of sicknessa 1 (0.2–8) 1 (0.1–22)
Height, m 1.7 (1.6–1.86) 1.7 (1.61–1.88)
Weight, kg 62 (53–90) 65 (44–101)
Hemoglobin, g/dL 14.0 (11.7–16.2) 12.7 (11.6–14.9)
Erythrocyte volume fraction 0.39 (0.32–0.45) 0.38 (0.37–0.41)
Leukocyte count, 109/L 10.2 (7.4–14.3) 10.1 (6.3–12.9)
Platelet count, 109/L 375 (227–844) 457 (167–640)
C-reactive protein, mg/La 21 (8–54) 9 (4–171)
Albumin, mg/L 40 (31–46) 41 (33–44)
Calprotectin, mg/mga 181 (32–531) 220 (46–1279)
CDAI 374 (174–462) 246 (160–288)
There were no statistical differences between the groups (Student’s t test/Mann–Whitney
U test).
aMann–Whitney U test.
CDAI, Crohn’s disease activity index.
Inﬂamm Bowel Dis  Volume 20, Number 11, November 2014 Perfusion and treatment outcome in CD
www.ibdjournal.org | 2033
proper muscle layer was signiﬁcantly thicker after 1 month and,
the submucosa layer was signiﬁcantly thicker after 3 months in
the group with ineffective treatment (Fig. 3).
Finally, there were no signiﬁcant differences in perfusion
parameters at time 0 and at 3 and 12 months. However, 1 month
after the initiation of the treatment, there was a signiﬁcant
difference between the 2 groups for the amplitude-based param-
eters’ peak enhancement (P ¼ 0.013), wash-in area under the
curve (P ¼ 0.013), wash-in rate (P ¼ 0.020), and wash-out rate
(P ¼ 0.008) (Fig. 4). The results for the 2 remaining amplitude-
based parameters’ wash-out area under the curve (P ¼ 0.142) and
wash-in/wash-out area under the curve (P ¼ 0.059) were not
signiﬁcant. There was no signiﬁcant difference at any point in
the time-related variables (Fig. 5) between the groups.
DISCUSSION
We found that patients with treatment failure after acute
exacerbation of CD had increased relative perfusion and a thickened
proper muscle layer compared with those with effective treatment
1 month after the start of treatment. The examination at this time
was performed before any change in therapy and could thus predict
the treatment outcome. To our knowledge, this principal ﬁnding
with an early (1 mo) evaluation of treatment effect has not been
presented earlier, although Quaia et al24 found a signiﬁcant differ-
ence between responders and nonresponders 3 months after the
start of treatment during a follow-up study.
Our study indicates that patients who have an early
therapeutic effect have lower local perfusion, which might
separate them from patients with poor or no effect. Thus,
perfusion evaluated with CEUS may be helpful in follow-up
and treatment of patients with CD. Current research implies that
angiogenesis correlate with disease activity.9,33 Consequently,
quantitative assessments of contrast-enhanced ultrasonograhic
sequences seem to provide a deeper understanding of the patho-
physiology in IBD.
It has previously been shown that contrast enhancement
with CEUS corresponds well with endoscopy34 and CDAI14 and
FIGURE 3. Thickness of the intestinal wall and wall layers during follow-up examinations. The box plots colored in green represents the patients
with treatment failure, whereas patients with effective treatment are represented in box plots colored in blue. A, Displays the bowel wall. B–D,
Presents the thickness of the wall layers mucosa, submucosa, and proper muscle, respectively.
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can predict disease relapse in CD.35 The degree of contrast
enhancement is however dependent on several other confounding
factors, such as contrast method and equipment used, depth of
lesion and shadowing from air, or arteries ﬁlled with contrast.6
This can partly be solved by scaling the data, but although it
relates to microvessel density, it does not describe the dynamic
element of perfusion since the transit of blood through the tissue is
not recorded. DCE-US includes time-intensity data and could thus
tell us more of the pathophysiology.
Quaia et al used a scaled time-intensity analysis and found
that there was a signiﬁcant difference in the area under the curve
between treatment responders (fall in CDAI $70 points) and
nonresponders after 3 months. The study cannot be directly com-
pared with ours due to a different outcome, but the results do
partly correspond. There was, however, no difference in peak
enhancement, and data on enhancement rate were not shown. This
study was performed on video data that are a log-compressed
version of the actual ultrasound intensities, which is mathemati-
cally incorrect.36 In our study, the linear data were reconstructed
from the video, which may be the reason why we found a signif-
icant difference for the peak enhancement and wash-in and wash-
out rates.
We found that some amplitude-related perfusion parameters
1 month after treatment start were not signiﬁcantly different, but
there seems to be a group effect. As a limited amount of patients
were included, it is possible that the nonsigniﬁcant results are due
to type 2 errors. Regarding the perfusion parameter wash-out area
under the curve, it is possible that this was not signiﬁcantly
different between the groups because of another aspect of the
study design. In our study, all CEUS recordings lasted 60
seconds, which could be too short for evaluating wash-out of
contrast agents. When assessing wash-in/wash-out area under the
curve, a similar argument could be used because the parameter is
inﬂuenced by the wash-out area under the curve (Table 1). Longer
time recordings may consequently be necessary in future studies.
FIGURE 4. Box-plot representation of the contrast analysis related to signal intensities in patients with active CD 1 month after initiating medical
treatment. Group 1 (blue boxes) responded well to the treatment, whereas group 2 (green boxes) had treatment failure. The ﬁgure displays
signiﬁcant differences (Mann–Whitney U test) between the groups for the perfusion parameters peak enhancement, wash-in area under the curve,
wash-in rate and wash-out rate.
FIGURE 5. Box-plot representation of the results from the time-related
variables such as rise time, fall time, and mean transit time in patients
with active CD 1 month after initiating medical treatment. Group 1
(blue boxes) responded well to the treatment, whereas group 2 (green
boxes) had treatment failure. There were no signiﬁcant differences
between the groups (Mann–Whitney U test).
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The time-related perfusion parameters (rise time, fall time,
and mean transit time) were not signiﬁcantly different. This could
be due to possible weaknesses in the study design or in the
perfusion modeling. When injecting an intravenous bolus and
analyzing contrast intensity over time, the bolus proﬁle is
dependent in the arterial input function (AIF). The AIF, however,
is dependent on injection speed, distance from injection site to
observed area, and interindividual differences in the blood vessel
system and blood volume. The bolus injection was manual, but
standardized. A mechanical injection using an automated pump
could reduce the variability in bolus administration, but cannot
correct the patient-speciﬁc variability. Recently, Jirik et al37 pro-
vided a new pharmacokinetic model combining bolus injection
and burst replenishment, which could overcome this problem by
providing an AIF estimate.
When comparing the thickness of the bowel wall between
those with effective and ineffective primary treatment, a signiﬁcant
difference between the groups was expected. In our pilot study,
we could not reveal such a difference (Fig. 3). It is reasonable to
assume this is also due to a type 2 error. When analyzing the
individual bowel wall layers, however, there was a signiﬁcant
difference between thickness of the proper muscle layer after 1
month and in the submucosa layer after 3 months. In CD, thick-
ening of the proper muscle layer is associated with patients with
ﬁbrosis in the GI wall,7 whereas thickening of the submucosa
layer is associated with inﬂammation.7,38 With closer examination
of the box plots in Figure 3, one could suspect that the proper
muscle layer is thicker in the treatment failure group also before
the treatment, although this result is not signiﬁcant. If these
patients already have developed a degree of ﬁbrosis in the GI
wall, this may explain why they are less responsive to treatment.
One might argue that measuring the thickness of the proper
muscle layer is simpler than estimating perfusion and that this
parameter alone seems promising for predicting treatment outcome.
Although inﬂammation is necessary to trigger the process of ﬁbrosis,
it seems that it is not necessary for perpetuating it. In fact, once
started, the ﬁbrotic process can run without ongoing inﬂammation.39
It would therefore be reasonable to use markers of both inﬂammation
and ﬁbrosis when evaluating treatment effect in patients. Increased
perfusion could indicate ongoing inﬂammation, whereas thickening
of the proper muscle layer could indicate worsening ﬁbrosis.
The major limitation of the study is the small number of
included patients. Although the examiner was masked to the
patient endpoints, the contrast analysis was performed by the
same examiner in all cases. Interobserver agreement should be
determined in future studies. Furthermore, all analyses were
performed using the same quantiﬁcation software. In future work,
comparison of different perfusion modalities could contribute to
increase the reliability of the results. The interindividual differ-
ences according to blood ﬂow could not be standardized, which
might have inﬂuenced the result. Consequently, a study including
more patients is required, and future studies should also compare
the results according to other outcomes, such as resection,
endoscopic remission, and clinical remission.
In conclusion, CEUS enables high-resolution perfusion
analysis of the intestinal wall. One month after starting treatment
in patients with CD, prognostic information regarding treatment
response can be obtained by ultrasound scanning of the bowel.
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